Compare BLNK & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | ZURA |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 455.4M |
| IPO Year | 2008 | N/A |
| Metric | BLNK | ZURA |
|---|---|---|
| Price | $0.63 | $5.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.33 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $1.26 |
| 52 Week High | $2.65 | $7.25 |
| Indicator | BLNK | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 59.46 |
| Support Level | $0.63 | $4.22 |
| Resistance Level | $0.73 | $5.82 |
| Average True Range (ATR) | 0.04 | 0.46 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 52.40 | 66.40 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from the U.S.A.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.